Chairman of the Board
Chief Medical Officer and Executive Vice-President, PanOptica, Inc.
Martin B. Wax, M.D., is chief medical officer and executive vice president of R&D at PanOptica, Inc., a private biotechnology company specializing in ophthalmic pharmaceuticals. He previously served as vice president of R&D and head of discovery research and preclinical sciences at Alcon Laboratories, where he was responsible for the creation and early development of the Alcon pharmaceutical portfolio.
Dr. Wax received his medical degree from the University of Southern California in Los Angeles. He completed his residency in Ophthalmology at Wills Eye Hospital in Pennsylvania, and post-doctoral fellowships in molecular pharmacology and glaucoma at the University of Pennsylvania School of Medicine.
He currently holds an appointment as a Professor of Ophthalmology and Visual Sciences at the University of Texas Southwestern Medical School in Dallas, and has been selected as one of the “Best Doctors in America” by his peers. An internationally recognized scientific expert in the field of glaucoma, Dr. Wax has co-authored more than 200 publications and serves on several scientific advisory committees and editorial boards.
Read More »
Venture Partner, Teralys Capital
Cédric Bisson is venture partner at Teralys Capital where he leads activities in healthcare and life sciences. Teralys Capital is Canada’s largest technology-focused fund of funds financing private venture capital funds that invest in information technology, life sciences and cleantech companies. Until he joined Teralys, Mr. Bisson was managing partner for healthcare at iNovia Capital in Montreal and Calgary, a private venture capital firm aimed at entrepreneurship and company building, during which he also created MSBi Valorisation, a seed technology transfer and investor firm focused principally on McGill University.
Mr. Bisson was previously an associate principal at McKinsey & Company, a global management consulting firm, where he was a leader in the healthcare and innovation practices in Montreal, New York City and Paris.
In his community time, Mr. Bisson serves as chairman of the board of the Biennale de Montréal and chairman of the board of Procure (non-profit charity against prostate cancer). He obtained a M.D. degree from McGill University and a J.D. (law) degree from Universite de MontrealSee More »
President & Chief Executive Officer
Sena Biswas, PhD, MBA Chief Executive Officer joined the BOD of Mimetogen in 2009, leading the structuring and negotiation of the company's transactions with Bausch & Lomb and Allergan plc.
Prior to joining Mimetogen as CEO, he was with the Corporate Development Group at Ora, where he focused on raising ophthalmology dedicated financing vehicles as well as executing licensing transactions and equity investments in ophthalmology companies. Previously, he was a Managing Director at VIMAC Milestone Medica, a biotechnology venture incubator which invested and managed early-stage companies.
He was the first employee and Founding President of Merrimack Pharmaceuticals which subsequently grew to a peak market capitalization of over $1.5B and successfully launched a cancer drug. Earlier in his career, held roles of Director of Business Development at Rhone-Poulenc Rorer executing over 100 licensing and M&A transactions, Principle at TL Ventures where he invested in the Series A rounds of Esperion, Adolor, ViroPharma, all of which became NASDAQ listed companies, and an Associate with the Healthcare Investment Banking team currently at JP Morgan, advising biopharmaceutical clients on M&A, equity, and debt financing transactions.
He holds a BA in Biology from Brandeis University, a PhD in Molecular and Cellular Biology from the University of Pennsylvania, an MBA from the Wharton School, and completed a postdoctoral fellowship in Molecular Immunology at Harvard Medical School.
Mr. Kevin Giese was the founder of BioMS Medical Corp. which company raised over $280 million, and in 2008 was designated Biotech Company of the year in Canada and awarded the Scrips Award for Best International Licensing Deal.
Mr. Giese has been on the board of directors of a number of private and publicly listed companies, including Spectral Diagnostics Inc. since March 2010, and Mimetogen Pharmaceuticals Inc. since October 2011.
He has been a member of the board of directors of BioAlberta, an advisory member of the Institute of Corporate Directors (Canada) and has received awards for entrepreneurship from BioAlberta and Ernst & Young. Mr. Giese has a B.A., a law degree and an M.B.A.